Hester Biosciences saw a 22% boost in Q4 revenues, primarily attributed to success in the Poultry Healthcare sector. The impressive 174% increase in profit after tax (PAT) can be credited to successful new vaccine launches.

Hester Biosciences' Q4 net profit surged significantly, reaching ₹15.9 crore compared to ₹1.2 crore in the same period last year. The company also reported a 22% increase in revenue to ₹100 crore and an impressive 78% rise in EBITDA, with a 34.2% margin.

Hester Biosciences is offering a Rs 11/share dividend, indicating robust investor rewards due to the company's impressive business results.

Hester Biosciences reported a significant 22% increase in Q4 revenue, reaching Rs. 1 billion, demonstrating notable growth compared to last year's figure of Rs. 819 million.